Negen partners with BC Platforms for early risk assessment of common diseases

Tuesday, September 4, 2018

Negen is excited to announce a cooperation agreement with BC Platforms, a leading provider of genomic data management and analytics. Negen’s advanced Genetic Risk Scoring tools will be integrated with BC Platforms’ state-of-the-art genomic data management platform, leading to advances in data processing and interpretation. Working together, these two leading genomics data companies will provide a premium, integrated solution to healthcare providers and customers around the world.

Negen, a company founded by Finnish geneticists and physicians, is the first to provide disease risk predictions that incorporate known genetic variants that predispose an individual to common diseases, with lifestyle risk factors. This integrated Genetic Risk Score gives healthcare providers more confidence in prescribing the correct preventive action or treatment, and has been proven to help motivate individuals to adopt a healthier lifestyle.

“We are delighted to partner with BC Platforms, a global leader in the integration and interpretation of genomic and clinical data. This partnership will greatly increase the awareness and utility of our Genetic Risk Scoring tools and our automatized genetic data interpretation. We look forward to bringing the benefits to both clinicians and patients,” says Kimmo Aro, CEO of Negen.

"With the increased adoption of precision medicine, we are noticing that more of our customers are demanding capability for populations-based precision medicine initiatives that require access to credible genetic risk scoring tools. This increase in demand is occurring due to technological advancements in handling and processing complex genomic data. We are pleased to partner with Negen to add this downstream capability to our platform," explained Tero Silvola, the CEO of BC Platforms.

About Negen

Negen is a genetic technology company founded by Finnish geneticists and physicians. Negen provides tools to prevent common chronic diseases, such as type 2 diabetes and coronary heart disease based on genetic profiling combined with commonly known measurable risk factors.

With the help of our automatised process algorithms, we can assess individual predisposition for a disease before any other method with highest accuracy available today in easily understandable and human readable format.

This information is proven to help individuals to re-evaluate individual lifestyle choices and help physicians to adjust the care or treatment path for successful disease prevention and cost savings in health care.

About BC Platforms

BC Platforms is a world leader in providing powerful genomic data management and analysis solutions. Our high performing genomic data management platform enables flexible data integration, secure analysis and interpretation of molecular and clinical information. The company has launched and opened a global network of biobanks, known as BCRQUEST.COM, to provide genomic and clinical cohort data for pharmaceutical and medical research and development. BC Platforms' vision is to build the world's leading analytics platform for healthcare and industry by 2020, providing access to diverse genomic and clinical data and samples from more than five million subjects consolidated from a global network of biobanks.

Founded in 1997 from an MIT Whitehead project spinoff, the Company has a strong scientific heritage underpinned by over 20 years of working in close collaboration with a network of leading researchers, developers, manufacturers and vendors. BC Platforms has global operations with its headquarters in Basel, Switzerland, research and development in Helsinki, Finland, and sales and marketing in London, Boston, and Vancouver.

For more information, please visit http://www.bcplatforms.com or @BCPlatforms on Twitter.

Share this

Negen to feature in HIMSS Europe 2019

This year, HIMSS Europe, the premier event in digital health, will be held in Finland (11.-13.6). Messukeskus Helsinki expects thousands of participants from around the world representing ministries, hospitals, and health technology companies.

More

Negen genomic analyses now available via Terveystalo

Finland’s largest health service provider Terveystalo maintains its role as pioneer by being the first to include Negen’s genomic tests in its offering.

Read More

Genomic testing provides the earliest indication of elevated disease risk

Early identification of disease risk enables effective prevention, which translates to more years of healthy living for the individual and significantly reduced healthcare costs.

Read More